Forxiga Neuseeland - Englisch - Medsafe (Medicines Safety Authority)

forxiga

astrazeneca limited - dapagliflozin propanediol monohydrate 12.3mg equivalent to dapaglifozin 10mg;   - film coated tablet - 10 mg - active: dapagliflozin propanediol monohydrate 12.3mg equivalent to dapaglifozin 10mg   excipient: colloidal silicon dioxide crospovidone opadry ii yellow lactose magnesium stearate microcrystalline cellulose - monotherapy forxiga is indicated in adults with type 2 diabetes mellitus as monotherapy as an adjunct to diet and exercise in patients for whom metformin is otherwise indicated but was not tolerated. initial combination forxiga is indicated in adults with type 2 diabetes mellitus as initial combination therapy with metformin, as an adjunct to diet and exercise, to improve glycaemic control when diet and exercise have failed to provide adequate glycaemic control and there are poor prospects for response to metformin monotherapy. add-on combination forxiga is indicated in adult patients with type 2 diabetes mellitus in combination with other anti-hyperglycaemic agents to improve glycaemic control, when these together with diet and exercise do not provide adequate glycaemic control. prevention of hospitalisation for heart failure forxiga is indicated in adults with type 2 diabetes mellitus and established cardiovascular disease or risk factors for cardiovascular disease to reduce the risk of hospitalisation for heart. prevention of new or worsening nephropathy forxiga is indicated in adults with type 2 diabetes mellitus and established cardiovascular disease or risk factors for cardiovascular disease for the prevention of new or worsening nephropathy.

Pancuronium Bromide (AstraZeneca) Neuseeland - Englisch - Medsafe (Medicines Safety Authority)

pancuronium bromide (astrazeneca)

astrazeneca limited - pancuronium bromide 2 mg/ml - solution for injection - 4 mg/2ml - active: pancuronium bromide 2 mg/ml excipient: acetic acid sodium acetate trihydrate sodium chloride sodium hydroxide water for injection - an adjunct to surgical anaesthesia to induce skeletal muscle relaxation to facilitate operative manipulations. the necessary conditions for intubation can be achieved with pancuronium alone or following suxamethonium. to promote mechanical ventilation by reducing or eliminating spontaneous breathing effort in intensive care patients.

QTERN 5/10 saxagliptin (as hydrochloride) / dapagliflozin (as propanediol monohydrate) 5 mg / 10 mg film-coated tablet blister pack Australien - Englisch - Department of Health (Therapeutic Goods Administration)

qtern 5/10 saxagliptin (as hydrochloride) / dapagliflozin (as propanediol monohydrate) 5 mg / 10 mg film-coated tablet blister pack

astrazeneca pty ltd - dapagliflozin propanediol monohydrate, quantity: 12.3 mg (equivalent: dapagliflozin, qty 10 mg); saxagliptin, quantity: 5 mg - tablet - excipient ingredients: microcrystalline cellulose; magnesium stearate; lactose; croscarmellose sodium; silicon dioxide; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; indigo carmine aluminium lake; ethanol; shellac; sulfuric acid - qtern 5/10 is indicated as an adjunct to diet and exercise, in combination with metformin, to improve glycaemic control in adults with type 2 diabetes mellitus when treatment with both saxagliptin and dapagliflozin is appropriate.

LYNPARZA olaparib 50 mg capsule bottle Australien - Englisch - Department of Health (Therapeutic Goods Administration)

lynparza olaparib 50 mg capsule bottle

astrazeneca pty ltd - olaparib, quantity: 50 mg - capsule - excipient ingredients: gellan gum; hypromellose; titanium dioxide; potassium acetate; lauroyl macrogolglycerides; iron oxide black; shellac - olaparib is indicated as monotherapy for the maintenance treatment of patients with platinum-sensitive relapsed brca-mutated (germline or somatic) high grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete response or partial response) after platinum-based chemotherapy. prior treatment must have included at least 2 courses of platinum-based regimens.

AG-QUETIAPINE TABLET (IMMEDIATE RELEASE) Kanada - Englisch - Health Canada

ag-quetiapine tablet (immediate release)

angita pharma inc. - quetiapine (quetiapine fumarate) - tablet (immediate release) - 25mg - quetiapine (quetiapine fumarate) 25mg - atypical antipsychotics

AG-QUETIAPINE TABLET (IMMEDIATE RELEASE) Kanada - Englisch - Health Canada

ag-quetiapine tablet (immediate release)

angita pharma inc. - quetiapine (quetiapine fumarate) - tablet (immediate release) - 100mg - quetiapine (quetiapine fumarate) 100mg - atypical antipsychotics

AG-QUETIAPINE TABLET (IMMEDIATE RELEASE) Kanada - Englisch - Health Canada

ag-quetiapine tablet (immediate release)

angita pharma inc. - quetiapine (quetiapine fumarate) - tablet (immediate release) - 200mg - quetiapine (quetiapine fumarate) 200mg - atypical antipsychotics

AG-QUETIAPINE TABLET (IMMEDIATE RELEASE) Kanada - Englisch - Health Canada

ag-quetiapine tablet (immediate release)

angita pharma inc. - quetiapine (quetiapine fumarate) - tablet (immediate release) - 300mg - quetiapine (quetiapine fumarate) 300mg - atypical antipsychotics

AG-ROSUVASTATIN CALCIUM TABLET Kanada - Englisch - Health Canada

ag-rosuvastatin calcium tablet

angita pharma inc. - rosuvastatin (rosuvastatin calcium) - tablet - 5mg - rosuvastatin (rosuvastatin calcium) 5mg - hmg-coa reductase inhibitors

AG-ROSUVASTATIN CALCIUM TABLET Kanada - Englisch - Health Canada

ag-rosuvastatin calcium tablet

angita pharma inc. - rosuvastatin (rosuvastatin calcium) - tablet - 10mg - rosuvastatin (rosuvastatin calcium) 10mg - hmg-coa reductase inhibitors